The Vulnerable Plaque
Editat de Ron Waksman, Patrick W. Serruys, Johannes Schaaren Limba Engleză Hardback – iun 2007
Preț: 818.72 lei
Preț vechi: 861.87 lei
-5%
Puncte Express: 1228
Preț estimativ în valută:
156.86€ • 169.91$ • 134.51£
156.86€ • 169.91$ • 134.51£
Cartea nu se mai tipărește
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781841846217
ISBN-10: 184184621X
Pagini: 490
Ilustrații: 63 b/w images
Dimensiuni: 195 x 247 x 32 mm
Greutate: 1.72 kg
Ediția:Revizuită
Editura: Informa Medical
Locul publicării:United Kingdom
ISBN-10: 184184621X
Pagini: 490
Ilustrații: 63 b/w images
Dimensiuni: 195 x 247 x 32 mm
Greutate: 1.72 kg
Ediția:Revizuită
Editura: Informa Medical
Locul publicării:United Kingdom
Public țintă
Cardiologists.Cuprins
Definition and Terminology of the Vulnerable Plaque. Pathology of the Vulnerable Plaque. Molecular Basics of Vulnerable Plaque. Genetics of the Vulnerable Plaque. Platelets and Vulnerable Plaque. Macrophages: Good, Bad or Ugly?. Metalloproteinase. VP: An Immunology Disease. Oxidative Stress and Vulnerability. Carotid VP. Diabetes Mellitus and VP. Psychological Triggers for Plaque Rupture. Animal Models. The Endothelial Markers. Biomarkers. Epidemiology of LpPLA2. Inhibition of LpPLA2. Angiography. Imaging the Vulnerable Plaque by Ultrasound. Palpography. Infrared Spectroscopy. Virtual Histology. Functional Measurement for Vulnerable Plaque Detection. Vulnerable Plaque and Shear Stress. Vasa Vasorum and Vulnerable Plaques. Intravascular MRI. Thermography: Basic Principles. Thermography: Clinical Aspects. Targeted Contrast. Nuclear Imaging of Vulnerable Plaques. Nanoparticels. MSCT. MRI. Vaccination: Bench. Vaccination: Bedside. Immunisation. Statins. Beyond Statins, Pharmaceutical Therapies for the Vulnerable Plaque. Stem Cell Therapy. Phototherapy. Stents for VP Treatment. Clinical Perspective of the Vulnerable Plaque. New Mechanisms for the Vulnerable Plaque. Prospect. IBIS. Prevail. Regulatory Issues of the FDA. Economics / Reimbursement. The Investors View